Making a diagnosis of Kawasaki disease with certainty may be challenging, especially since the recognition of cases with incomplete diagnostic criteria and its consequences. In order to build the diagnostic case in daily practice, clinicians rely on clinical criteria established over four decades ago, aided by non specific laboratory tests, and above all inspired by experience. We have recently studied the diagnostic value of N-terminal pro B-type natriuretic peptide to improve the diagnostic certainty of cases with complete or incomplete clinical criteria. Our working hypothesis was based on the fact that myocarditis is present in nearly all Kawasaki disease patients supported by histology data. In this paper, we review these facts and the myocardial perspective from the diagnostic and the mechanistic standpoints.
References
[1]
Freeman, A.F.; Shulman, S.T. Kawasaki disease: Summary of the American heart association guidelines. Am. Fam. Physician 2006, 74, 1141–1148.
[2]
Burns, J.C.; Newburger, J.W. Genetics insights into the pathogenesis of Kawasaki disease. Circ. Cardiovasc. Genet. 2012, 5, 277–278, doi:10.1161/CIRCGENETICS.112.963710.
[3]
Onouchi, Y. Genetics of Kawasaki disease: What we know and don’t know. Circ. J. 2012, 76, 1581–1586, doi:10.1253/circj.CJ-12-0568.
[4]
Amano, S.; Hazama, F.; Kubagawa, H.; Tasaka, K.; Haebara, H.; Hamashima, Y. General pathology of Kawasaki disease. On the morphological alterations corresponding to the clinical manifestations. Acta Pathol. Jpn. 1980, 30, 681–694.
[5]
Fujiwara, H.; Hamashima, Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978, 61, 100–107.
[6]
Kawasaki, T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967, 16, 178–222.
[7]
Shigematsu, I.; Tamashiro, H.; Shibata, S.; Kawasaki, T.; Kusakawa, S. Kawasaki disease: A worldwide survey. Lancet. 1979, 2, 193.
[8]
Rose, V.; Lightfoot, N.E.; Fournier, A.; Gibbons, J.E. The descriptive epidemiology of Kawasaki syndrome in Canada, 1979–1985. Prog. Clin. Biol. Res. 1987, 250, 45–53.
[9]
John, T.J.; DeBenedetti, C.D.; Zee, M.L. Mucocutaneous lymph node syndrome in Arizona. Amer. J. Dis. Child. 1976, 130, 613–614.
[10]
Manlhiot, C.; Yeung, R.S.; Clarizia, N.A.; Chahal, N.; McCrindle, B.W. Kawasaki disease at the extremes of the age spectrum. Pediatrics 2009, 124, e410–e415, doi:10.1542/peds.2009-0099.
[11]
Nakamura, Y.; Yanagawa, H.; Kawasaki, T. Mortality among children with Kawasaki disease in Japan. NEJM 1992, 326, 1246–1249, doi:10.1056/NEJM199205073261903.
Newburger, J.W.; Takahashi, M.; Beiser, A.S.; Burns, J.C.; Bastian, J.; Chung, K.J.; Colan, S.D.; Duffy, C.E.; Fulton, D.R.; Glode, M.P.; et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. NEJM 1991, 324, 1633–1639.
[14]
Kuramochi, Y.; Ohkubo, T.; Takechi, N.; Fukumi, D.; Uchikoba, Y.; Ogawa, S. Hemodynamic factors of thrombus formation in coronary aneurysms associated with Kawasaki disease. Pediatr. Int. 2000, 42, 470–475, doi:10.1046/j.1442-200x.2000.01270.x.
[15]
Lapierre, C.; Bitsch, A.; Guérin, R.; Garel, L.; Miró, J.; Dahdah, N. Follow-up chest X-ray in patients with Kawasaki disease: the significance and clinical application of coronary artery macro-calcification. Pediatr. Cardiol. 2010, 31, 56–61, doi:10.1007/s00246-009-9548-5.
[16]
Tsuda, E.; Kamiya, T.; Ono, Y.; Kimura, K.; Kurosaki, K.; Echigo, S. Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. Pediatr. Cardiol. 2005, 26, 73–79, doi:10.1007/s00246-004-0698-1.
[17]
Portman, M.A.; Olson, A.; Soriano, B.; Dahdah, N.; Williams, R.; Kirkpatrick, E. Etanercept as adjunctive treatment for acute Kawasaki disease: Study design and rationale. Amer. Heart J. 2011, 161, 494–499, doi:10.1016/j.ahj.2010.12.003.
[18]
Son, M.B.; Gauvreau, K.; Burns, J.C.; Corinaldesi, E.; Tremoulet, A.H.; Watson, V.E.; Baker, A.; Fulton, D.R.; Sundel, R.P.; Newburger, J.W. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: A retrospective study. J. Pediatr. 2011, 158, 644–649, doi:10.1016/j.jpeds.2010.10.012.
[19]
Newburger, J.W.; Takahashi, M.; Gerber, M.A.; Gewitz, M.H.; Tani, L.Y.; Burns, J.C.; Shulman, S.T.; Bolger, A.F.; Ferrieri, P.; Baltimore, R.S.; et al. Diagnosis, treatment, and long-term management of Kawasaki disease. A statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Circulation 2004, 110, 2747–2771.
[20]
Cimaz, R.; Sundel, R. Atypical and incomplete Kawasaki disease. Best Pract. Res. Clin. Rheumatol. 2009, 23, 689–697, doi:10.1016/j.berh.2009.08.010.
[21]
Ghelani, S.J.; Sable, C.; Wiedermann, B.L.; Spurney, C.F. Increased incidence of incomplete Kawasaki disease at a pediatric hospital after publication of the 2004 American heart association guidelines. Pediatr. Cardiol. 2012, 33, 1097–1103, doi:10.1007/s00246-012-0232-9.
[22]
Tremoulet, A.H.; Jain, S.; Chandrasekar, D.; Sun, X.; Sato, Y.; Burns, J.C. Evolution of laboratory values in patients with Kawasaki disease. Pediatr. Infect. Dis. J. 2011, 30, 1022–1026, doi:10.1097/INF.0b013e31822d4f56.
[23]
Sudo, D.; Monobe, Y.; Yashiro, M.; Mieno, M.N.; Uehara, R.; Tsuchiya, K.; Sonobe, T.; Nakamura, Y. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur. J. Pediatr. 2012, 171, 651–656, doi:10.1007/s00431-011-1630-3.
[24]
Ayusawa, M.; Sonobe, T.; Uemura, S.; Ogawa, S.; Nakamura, Y.; Kiyosawa, N.; Ishii, M.; Harada, K.; Kawasaki disease research committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr. Int. 2005, 47, 232–234.
[25]
Muta, H.; Ishii, M.; Yashiro, M.; Uehara, R.; Nakamura, Y. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics 2012, 129, e291–e297, doi:10.1542/peds.2011-1704.
[26]
Fujiwara, H.; Hamashima, Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978, 61, 100–107.
[27]
Harada, M.; Yokouchi, Y.; Oharaseki, T.; Matsui, K.; Tobayama, H.; Tanaka, N.; Akimoto, K.; Takahashi, K.; Kishiro, M.; Shimizu, T.; Takahashi, K. Histopathological characteristics of myocarditis in acute-phase Kawasaki disease. Histopathology 2012, 61, 1156–1167, doi:10.1111/j.1365-2559.2012.04332.x.
Liu, AM.; Ghazizadeh, M.; Onouchi, Z.; Asano, G. Ultrastructural characteristics of myocardial and coronary microvascular lesions in Kawasaki disease. Microvasc. Res. 1999, 58, 10–27, doi:10.1006/mvre.1999.2155.
[30]
Kao, C.; Hsieh, K.; Wang, Y.; Chen, C.W.; Liao, S.Q.; Wang, S.J.; Yeh, S.H. Tc-99m HMPAO labeled WBC scan for the detection of myocarditis in different phases of Kawasaki disease. Clin. Nucl. Med. 1992, 17, 185–190, doi:10.1097/00003072-199203000-00006.
Moran, A.M.; Newburger, J.W.; Sanders, S.P.; Parness, I.A.; Spevak, P.J.; Burns, J.C.; Colan, S.D. Abnormal myocardial mechanics in Kawasaki disease: Rapid response to gamma-globulin. Amer. Heart J. 2000, 139, 217–223.
[33]
Yonesaka, S.; Takahashi, T.; Matubara, T.; Nakada, T.; Furukawa, H.; Tomimoto, K.; Oura, H. Histopathological study on Kawasaki disease with special reference to the relation between the myocardial sequellae and regional wall motion abnormalities of the left ventricle. Jpn. Circ. J. 1991, 56, 352–358.
[34]
Yu, J.J.; Kwak, B.O.; Jeon, Y.H.; Park, Y.M.; Lee, R.; Chung, S.; Bae, S.H.; Pyun, B.Y. Elevation of the index of left ventricular mass during the acute and subacute phase of Kawasaki disease, and its association with indexes of diastolic function. Cardiol. Young 2009, 19, 64–69, doi:10.1017/S1047951108003405.
[35]
Printz, B.F.; Sleeper, L.A.; Newburger, J.W.; Minich, L.L.; Bradley, T.; Cohen, M.S.; Frank, D.; Li, J.S.; Margossian, R.; Shirali, G.; Takahashi, M.; Colan, S.D.; Pediatric heart network investigators. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J. Amer. Coll. Cardiol. 2011, 57, 86–92.
[36]
Yoshikawa, H.; Nomura, Y.; Masuda, K.; Hazeki, D.; Yotsumoto, K.; Arata, M.; Kamenosono, A.; Yanagi, S.; Yoshinaga, M.; Kawano, Y. Four cases of Kawasaki syndrome complicated with myocarditis. Circ. J. 2006, 70, 202–205.
[37]
McNeal-Davidson, A.; Fournier, A.; Spigelblatt, L.; Saint-Cyr, C.; Mir, T.S.; Nir, A.; Dallaire, F.; Cousineau, J.; Delvin, E.; Dahdah, N. Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease. Pediatr. Int. 2012, 54, 627–633, doi:10.1111/j.1442-200X.2012.03609.x.
Lim, G.W.; Lee, M.; Kim, H.S.; Hong, Y.M.; Sohn, S. Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion in Kawasaki disease. Korean Circ. J. 2010, 40, 507–513, doi:10.4070/kcj.2010.40.10.507.
[40]
Mori, J.; Miura, M.; Shiro, H.; Fujioka, K.; Kohri, T.; Hasegawa, T. Syndrome of inappropriate anti-diuretic hormone in Kawasaki disease. Pediatr. Int. 2011, 53, 354–357.
[41]
Nakabayashi, Y.; Shimizu, T. Hyponatremia in Kawasaki disease. Nippon Shoni Jinzobyo Gakkai Zasshi 2002, 15, 83–87, doi:10.3165/jjpn.15.83.
[42]
Kim, S.Y.; Kim, N.J.; Choi, J.S.; Hu, J.K. Clinical factors causing hyponatremia in patients with mucocutaneous lymph node syndrome. Korean J. Pediatr. 2009, 52, 364–369, doi:10.3345/kjp.2009.52.3.364.
Mine, K.; Takaya, J.; Hasui, M.; Ikemoto, Y.; Teraguchi, M.; Kobayashi, Y. A case of Kawasaki disease associated with syndrome of inappropriate secretion of antidiuretic hormone. Acta Paediatr. 2004, 93, 1547–1549, doi:10.1111/j.1651-2227.2004.tb02646.x.
[45]
Ichiyama, T.; Nishikawa, M.; Hayashi, T.; Koga, M.; Tashiro, N.; Furukawa, S. Cerebral hypoperfusion during acute Kawasaki disease. Stroke 1998, 29, 1320–1321.
[46]
Wu, J.M.; Chiou, Y.Y.; Hung, W.P.; Chiu, N.T.; Chen, M.J.; Wang, J.N. Urinary cytokines and renal Doppler study in Kawasaki disease. J. Pediatr. 2010, 156, 792–797, doi:10.1016/j.jpeds.2009.11.046.
Kato, H.; Ichinose, E.; Kawasaki, T. Myocardial infarction in Kawasaki disease: Clinical analyses in 195 cases. J. Pediatr. 1986, 108, 923–927.
[49]
Tsuda, E.; Kamiya, T.; Ono, Y.; Kimura, K.; Kurosaki, K.; Echigo, S. Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. Pediatr. Cardiol. 2005, 26, 73–79.
[50]
Tsuda, E.; Hirata, T.; Matsuo, O.; Abe, T.; Sugiyama, H.; Yamada, O. The 30-year outcome for patients after myocardial infarction due to coronary artery lesions caused by Kawasaki disease. Pediatr. Cardiol. 2011, 32, 176–182, doi:10.1007/s00246-010-9838-y.
[51]
Checchia, P.A.; Borensztajn, J.; Shulman, S.T. Circulating cardiac troponin I levels in Kawasaki disease. Pediatr. Cardiol. 2001, 22, 102–106, doi:10.1007/s002460010170.
[52]
Kim, M.; Kim, K. Elevation of cardiac troponin I in the acute stage of Kawasaki disease. Pediatr. Cardiol. 1999, 20, 184–188, doi:10.1007/s002469900437.
[53]
Kim, M.; Kim, K. Changes in cardiac troponin I in Kawasaki disease before and after treatment with intravenous gammaglobulin. Jpn. Circ. J. 1998, 62, 479–482, doi:10.1253/jcj.62.479.
[54]
Matsuura, H.; Ishikita, T.; Yamamoto, S.; Umezawa, T.; Ito, R.; Hashiguchi, R.; Saji, T.; Matsuo, N.; Takano, M. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome): The usefulness of single photon emission computed tomography. Br. Heart J. 1987, 58, 385–392, doi:10.1136/hrt.58.4.385.
[55]
Newburger, J.W.; Sanders, S.P.; Burns, J.C.; Parness, I.A.; Beiser, A.S.; Colan, S.D. Left ventricular contractility and function in Kawasaki syndrome; Effect of intravenous gamma globulin. Circulation 1989, 79, 1237–1246, doi:10.1161/01.CIR.79.6.1237.
[56]
Takahashi, M. Myocarditis in Kawasaki syndrome: A minor villain? Circulation 1989, 79, 1398–1400.
[57]
De Lemos, J.A.; Mcguire, D.K.; Draznermh, M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362, 316–322.
[58]
Nakao, K.; Ogawa, Y.; Suga, S.-I.; Imura, H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J. Hypertens. 1992, 10, 1111–1114.
[59]
Vanderheyden, M.; Bartunek, J.; Goethals, M. Brain and other natriuretic peptides: Molecular aspects. Eur. J. Heart Fail. 2004, 6, 261–268, doi:10.1016/j.ejheart.2004.01.004.
[60]
Wilson Tang, W.H. B-type natriuretic peptide: A critical review. CHF 2007, 13, 48–52.
[61]
Dahdah, N.; Siles, A.; Fournier, A.; Cousineau, J.; Delvin, E.; Saint-Cyr, C.; Spiegelblatt, L.; Bonny, Y.; Vartian, M.; Montigny, M. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr. Cardiol. 2009, 30, 810–817, doi:10.1007/s00246-009-9441-2.
[62]
Kishimoto, S.; Suda, K.; Teramachi, Y.; Nishino, H.; Kudo, Y.; Ishii, H.; Iemura, M.; Takahashi, T.; Okamura, H.; Matsuishi, T. Increased plasma type B natriuretic peptide in the acute phase of Kawasaki disease. Pediatr. Int. 2011, 53, 736–741, doi:10.1111/j.1442-200X.2011.03351.x.
[63]
Rowley, A.H.; Shulman, S.T. Nelson Textbook of Pediatrics, 18th ed.; Elsevier: Philadelphia, PA, USA, 2007; pp. 1036–1031.
[64]
Nir, A.; Lindinger, A.; Rauh, M.; Bar-Oz, B.; Laer, S.; Schwachtgen, L.; Koch, A.; Falkenberg, J.; Mir, T.S. NT-Pro-B-type natriuretic peptide in infants and children: Reference values based on combined data from four studies. Pediatr. Cardiol. 2009, 30, 3–8, doi:10.1007/s00246-008-9258-4.
[65]
Albers, S.; Mir, T.S.; Haddad, M.; L？er, S. N-terminal pro brain natriuretic peptide: Evaluation of pediatric reference values including method comparison and interlaboratory variability. Clin. Chem. Lab. Med. 2006, 44, 80–85.
[66]
Johns, M.C.; Stephenson, C. Amino-terminal pro-B-type natriuretic peptide testing in neonatal and pediatric patients. Amer. J. Cardiol. 2008, 101, 76–81, doi:10.1016/j.amjcard.2007.11.028.
[67]
Zhang, Q.Y.; Du, J.B.; Chen, Y.H.; Li, W.Z. Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice. Zhonghua Er Ke Za Zhi. 2006, 44, 886–890.
[68]
Lee, H.; Kim, H.; Kim, H.S.; Sohn, S. NT-pro BNP: A new diagnostic screening tool for Kawasaki disease. Korean J. Pediatr. 2006, 49, 539–544, doi:10.3345/kjp.2006.49.5.539.
[69]
Tremoulet, A.H.; Jain, S.; Chandrasekar, D.; Sun, X.; Sato, Y.; Burns, J.C. Evolution of laboratory values in patients with Kawasaki disease. Pediatr. Infect. Dis. J. 2011, 30, 1022–1026, doi:10.1097/INF.0b013e31822d4f56.
Kawamura, T.; Wago, M.; Kawaguchi, H.; Tahara, M.; Yuge, M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr. Int. 2000, 42, 241–248, doi:10.1046/j.1442-200x.2000.01225.x.
[72]
Bang, S.; Yu, J.J.; Han, M.K.; Ko, H.K.; Chun, S.; Choi, H.S.; Kim, Y.H.; Ko, J.K.; Park, I.S. Log-transformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction. Korean J. Pediatr. 2011, 54, 340–344, doi:10.3345/kjp.2011.54.8.340.
[73]
Kaneko, K.; Yoshimura, K.; Ohashi, A.; Kimata, T.; Shimo, T.; Tsuji, S. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr. Cardiol. 2011, 32, 1106–1109, doi:10.1007/s00246-011-9986-8.
[74]
Kim, H.K.; Oh, J.; Hong, Y.M.; Sohn, S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ. J. 2011, 41, 379–384, doi:10.4070/kcj.2011.41.7.379.
[75]
Suzuki, H.; Terai, M.; Hamada, H.; Honda, T.; Suenaga, T.; Takeuchi, T.; Yoshikawa, N.; Shibuta, S.; Miyawaki, M.; Oishi, K.; et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr. Infect. Dis. J. 2011, 30, 871–876, doi:10.1097/INF.0b013e318220c3cf.
[76]
Kanai, T.; Ishiwata, T.; Kobayashi, T.; Sato, H.; Takizawa, M.; Kawamura, Y.; Tsujimoto, H.; Nakatani, K.; Ishibashi, N.; Nishiyama, M.; et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: A retrospective study. Circulation 2011, 124, 2822–2828, doi:10.1161/CIRCULATIONAHA.111.028423.
[77]
Ogata, S.; Ogihara, Y.; Honda, T.; Kon, S.; Akiyama, K.; Ishii, M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: A randomized trial. Pediatrics 2012, 129, E17–E23, doi:10.1542/peds.2011-0148.
[78]
Onouchi, Y.; Suzuki, Y.; Suzuki, H.; Terai, M.; Yasukawa, K.; Hamada, H.; Suenaga, T.; Honda, T.; Honda, A.; Kobayashi, H.; et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J. 2011, doi:10.1038/Tpj.2011.45.
